Literature DB >> 23054562

Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET-PET.

Maximilian Niyazi1, Nathalie Jansen, Ute Ganswindt, Silke Birgit Schwarz, Julia Geisler, Oliver Schnell, Karen Büsing, Sabina Eigenbrod, Christian la Fougère, Claus Belka.   

Abstract

The aim of the present study is to determine new positron emission tomography (PET) imaging-related factors predictive of progression-free survival as well as survival in patients with recurrent malignant glioma (MG) prior to and after re-irradiation. Fifty-six patients with recurrent MG who underwent re-irradiation treatment and pretherapeutic dynamic [(18)F]-fluoroethyl-L-tyrosine (FET)-PET scan were retrospectively analyzed. The prognostic value of different parameters, such as biological tumor volume, maximal tumor uptake (SUV(max)/BG), mean tumor uptake (SUV(mean)/BG), as well as uptake kinetics, was evaluated. [(18)F]FET uptake kinetics was classified according to a five-point rating as category G(1-2) (strongly/mainly increasing kinetics), G(3) (mixed 1:1), or G(4-5) (mainly/strongly decreasing kinetics). Patients within the pretherapeutic kinetic group G(4-5) had significantly worse survival than the other two groups (p = 0.01). Multivariate analysis revealed that histologic grade, Karnofsky Performance Score (KPS), and kinetic group were independent significant predictors for survival after re-irradiation. The uptake kinetics of [(18)F]FET-PET is an independent determinant of overall and to a lesser extent also progression-free survival. Thus, [(18)F]FET-PET kinetics may provide valuable additional prognostic information for treatment decisions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23054562     DOI: 10.1007/s11060-012-0980-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  20 in total

1.  Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme.

Authors:  Marc D Piroth; Michael Pinkawa; Richard Holy; Jens Klotz; Sandra Nussen; Gabriele Stoffels; Heinz H Coenen; Hans J Kaiser; Karl J Langen; Michael J Eble
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

2.  Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.

Authors:  Marc D Piroth; Richard Holy; Michael Pinkawa; Gabriele Stoffels; Hans J Kaiser; Norbert Galldiks; Hans Herzog; Heinz H Coenen; Michael J Eble; Karl J Langen
Journal:  Radiother Oncol       Date:  2011-04-16       Impact factor: 6.280

Review 3.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

4.  Early change in glucose metabolic rate measured using FDG-PET in patients with high-grade glioma predicts response to temozolomide but not temozolomide plus radiotherapy.

Authors:  Natalie Charnley; Catharine M West; Carolyn M Barnett; Catherine Brock; Graeme M Bydder; Mark Glaser; Ed S Newlands; Ric Swindell; Julian Matthews; Pat Price
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-07-12       Impact factor: 7.038

5.  Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.

Authors:  Frank W Floeth; Dirk Pauleit; Michael Sabel; Gabriele Stoffels; Guido Reifenberger; Markus J Riemenschneider; Paul Jansen; Heinz H Coenen; Hans-Jakob Steiger; Karl-Josef Langen
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

6.  Survival and quality of life after hypofractionated stereotactic radiotherapy for recurrent malignant glioma.

Authors:  Antje Ernst-Stecken; Oliver Ganslandt; Ulrike Lambrecht; Rolf Sauer; Gerhard Grabenbauer
Journal:  J Neurooncol       Date:  2006-09-20       Impact factor: 4.130

7.  FET-PET for malignant glioma treatment planning.

Authors:  Maximilian Niyazi; Julia Geisler; Axel Siefert; Silke Birgit Schwarz; Ute Ganswindt; Sylvia Garny; Oliver Schnell; Bogdana Suchorska; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn; Peter Bartenstein; Christian la Fougère; Claus Belka
Journal:  Radiother Oncol       Date:  2011-03-30       Impact factor: 6.280

8.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

Review 9.  Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

Authors:  Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert
Journal:  J Clin Oncol       Date:  2008-09-01       Impact factor: 44.544

10.  Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.

Authors:  Marc D Piroth; Michael Pinkawa; Richard Holy; Gabriele Stoffels; Cengiz Demirel; Charbel Attieh; Hans J Kaiser; Karl J Langen; Michael J Eble
Journal:  Radiat Oncol       Date:  2009-11-23       Impact factor: 3.481

View more
  14 in total

1.  Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients.

Authors:  Ken Herrmann; Johannes Czernin; Timothy Cloughesy; Albert Lai; Kelsey L Pomykala; Matthias R Benz; Andreas K Buck; Michael E Phelps; Wei Chen
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

2.  Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET).

Authors:  Asma Bashir; Sofie Mathilde Jacobsen; Otto Mølby Henriksen; Helle Broholm; Thomas Urup; Kirsten Grunnet; Vibeke Andrée Larsen; Søren Møller; Jane Skjøth-Rasmussen; Hans Skovgaard Poulsen; Ian Law
Journal:  Neuro Oncol       Date:  2019-12-17       Impact factor: 12.300

3.  Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.

Authors:  Maya Flieger; Ute Ganswindt; Silke Birgit Schwarz; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn; Christian la Fougère; Lorenz Ertl; Jennifer Linn; Ulrich Herrlinger; Claus Belka; Maximilian Niyazi
Journal:  J Neurooncol       Date:  2014-02-07       Impact factor: 4.130

4.  18F-FET PET prior to recurrent high-grade glioma re-irradiation-additional prognostic value of dynamic time-to-peak analysis and early static summation images?

Authors:  Daniel F Fleischmann; Marcus Unterrainer; Peter Bartenstein; Claus Belka; Nathalie L Albert; Maximilian Niyazi
Journal:  J Neurooncol       Date:  2017-01-19       Impact factor: 4.130

Review 5.  Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis.

Authors:  Vincent Dunet; Anastasia Pomoni; Andreas Hottinger; Marie Nicod-Lalonde; John O Prior
Journal:  Neuro Oncol       Date:  2015-08-04       Impact factor: 12.300

6.  Impact of 18F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy.

Authors:  Charlotte Debus; Maria Waltenberger; Ralf Floca; Ali Afshar-Oromieh; Nina Bougatf; Sebastian Adeberg; Sabine Heiland; Martin Bendszus; Wolfgang Wick; Stefan Rieken; Uwe Haberkorn; Jürgen Debus; Maximilian Knoll; Amir Abdollahi
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

7.  Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.

Authors:  Norbert Galldiks; Maximilian Niyazi; Anca L Grosu; Martin Kocher; Karl-Josef Langen; Ian Law; Giuseppe Minniti; Michelle M Kim; Christina Tsien; Frederic Dhermain; Riccardo Soffietti; Minesh P Mehta; Michael Weller; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

8.  FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?

Authors:  Montserrat Carles; Ilinca Popp; Michael Maximilian Starke; Michael Mix; Horst Urbach; Tanja Schimek-Jasch; Franziska Eckert; Maximilian Niyazi; Dimos Baltas; Anca L Grosu
Journal:  Radiat Oncol       Date:  2021-03-03       Impact factor: 3.481

9.  Reirradiation in progressive high-grade gliomas: outcome, role of concurrent chemotherapy, prognostic factors and validation of a new prognostic score with an independent patient cohort.

Authors:  Felix Scholtyssek; Isabella Zwiener; Annika Schlamann; Clemens Seidel; Jürgen Meixensberger; Manfred Bauer; Karl-Titus Hoffmann; Stephanie E Combs; André O von Bueren; Rolf-Dieter Kortmann; Klaus Müller
Journal:  Radiat Oncol       Date:  2013-07-03       Impact factor: 3.481

10.  Validation of the prognostic Heidelberg re-irradiation score in an independent mono-institutional patient cohort.

Authors:  Maximilian Niyazi; Maya Flieger; Ute Ganswindt; Stephanie E Combs; Claus Belka
Journal:  Radiat Oncol       Date:  2014-06-03       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.